Houlihan Financial Resource Group Ltd. boosted its stake in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 4.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,714 shares of the company’s stock after acquiring an additional 202 shares during the quarter. Houlihan Financial Resource Group Ltd.’s holdings in Merck & Co., Inc. were worth $622,000 as of its most recent SEC filing.
Other large investors also recently added to or reduced their stakes in the company. Stonegate Investment Group LLC grew its position in Merck & Co., Inc. by 0.3% in the first quarter. Stonegate Investment Group LLC now owns 24,915 shares of the company’s stock valued at $3,288,000 after acquiring an additional 79 shares during the last quarter. NTV Asset Management LLC raised its stake in Merck & Co., Inc. by 0.3% during the 4th quarter. NTV Asset Management LLC now owns 26,534 shares of the company’s stock worth $2,893,000 after buying an additional 80 shares during the period. SRS Capital Advisors Inc. grew its holdings in shares of Merck & Co., Inc. by 1.6% during the fourth quarter. SRS Capital Advisors Inc. now owns 5,037 shares of the company’s stock valued at $549,000 after buying an additional 81 shares during the last quarter. Endowment Wealth Management Inc. lifted its position in Merck & Co., Inc. by 3.2% in the 4th quarter. Endowment Wealth Management Inc. now owns 2,637 shares of the company’s stock valued at $288,000 after acquiring an additional 81 shares in the last quarter. Finally, Hendershot Investments Inc. raised its stake in shares of Merck & Co., Inc. by 0.5% in the first quarter. Hendershot Investments Inc. now owns 15,756 shares of the company’s stock worth $2,079,000 after purchasing an additional 81 shares during the last quarter. 76.07% of the stock is owned by institutional investors.
Merck & Co., Inc. Stock Performance
Shares of NYSE:MRK traded down $1.21 during trading on Friday, hitting $127.76. The company’s stock had a trading volume of 6,995,589 shares, compared to its average volume of 8,405,373. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.25 and a quick ratio of 0.99. The firm has a market cap of $323.59 billion, a price-to-earnings ratio of 141.96, a P/E/G ratio of 2.46 and a beta of 0.38. The company has a 50-day moving average of $128.98 and a 200-day moving average of $125.57. Merck & Co., Inc. has a 12 month low of $99.14 and a 12 month high of $134.63.
Merck & Co., Inc. Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Monday, July 8th. Shareholders of record on Monday, June 17th were paid a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 2.41%. The ex-dividend date of this dividend was Monday, June 17th. Merck & Co., Inc.’s payout ratio is 342.22%.
Wall Street Analyst Weigh In
A number of analysts recently commented on MRK shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 price target on shares of Merck & Co., Inc. in a research report on Tuesday, June 18th. Argus upgraded shares of Merck & Co., Inc. to a “strong-buy” rating in a research report on Wednesday, June 5th. Morgan Stanley boosted their price objective on Merck & Co., Inc. from $132.00 to $134.00 and gave the company an “equal weight” rating in a research report on Thursday. Berenberg Bank upped their price objective on shares of Merck & Co., Inc. from $140.00 to $143.00 and gave the company a “buy” rating in a research note on Monday, April 8th. Finally, Truist Financial lifted their price objective on Merck & Co., Inc. from $142.00 to $143.00 and gave the stock a “buy” rating in a research report on Friday, April 26th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $134.33.
Check Out Our Latest Stock Report on MRK
Merck & Co., Inc. Company Profile
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
Featured Articles
- Five stocks we like better than Merck & Co., Inc.
- 3 Warren Buffett Stocks to Buy Now
- Top 3 Beverage Stocks: Summer Earnings Reveal Key Trends
- Stock Market Upgrades: What Are They?
- This Financial Stock’s Earnings Signal a Buying Opportunity
- The 3 Best Blue-Chip Stocks to Buy Now
- Social Platform Stock Hits New Highs: Is More Growth Ahead?
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.